A decrease in glucose uptake, lactate levels, and HK2 expression was also observed in human cancer cells harboring mutant BRAF and BRAF-driven melanoma xenografts following MEK1/2 inhibition [113], confirming a positive correlation between the glycolytic phenotype of cancer cells and BRAF/MEK/ERK pathway activation. The gene discussed is MAP2K7; the disease is melanoma.